The main research subject of our lab is 'Muse cells' which we found as a novel type of non-tumorigenic pluripotent stem cells.
They possess several properties that are not recognized in other stem cells.
Furthermore, they are collectable from easy accessible sources, and thus are feasible for clinical application.
We are propelling Muse cell project from the standpoint of basic research as well as of pre-clinical study.

Clinical trial of Muse cell therapy has started as below.

  1. Clinical trial of Muse cell product targetting acute myocardial infarction has started from February 2018. Press Releases
  2. Clinical trial of Muse cell product targetting ischemic stroke patient has started from September 2018. Press Releases
  3. Clinical trial of Muse cell product targetting epidermolysis bullosa has started from December 2018. Press Releases
  4. Clinical trial with a Muse cell product targetting spinal cord injuries has started from July 2019. Press Releases
  5. Clinical trial with Muse cell-based product in patients with amyotrophic lateral sclerosis has been started from January 2021. Press Releases
  6. Clinical trial of Muse cell-based product to treat acute respiratory distress syndrome (ARDS) related to novel coronavirus (SARS-CoV-2) infection has been started from April 2021. Press Releases

These clinical trials are conducted by Life Science Institute Inc., the group company of Mitsubishi Chemical holdings.

Re: Business Operations of SanBio Co., Ltd.

Recently, we received multiple inquiries about SanBio Co., Ltd. (Tokyo, Japan; hereinafter, "SanBio"), presumably based on a misunderstanding of the relationship between certain projects undertaken by this corporation and the Muse cell research that our laboratory promotes under the leadership of Prof. Mari Dezawa. Dr. Dezawa had been one of the founding scientists of SanBio, Inc. (CA, U.S.A.), a subsidiary of SanBio, but resigned in April 2010. Since then, Dr. Dezawa has dissolved the relationship with both SanBio, Inc. and SanBio. Dr. Dezawa and our laboratory are no longer involved in the development of SB623 cells or other SanBio projects. Therefore, neither Dr. Dezawa nor other members of our laboratory are responsible for any of SanBio's activities, products, or other business operations.
We wish to emphasize that Muse cells are totally different from, and have nothing to do with, the cells that SanBio and SanBio, Inc. developed. Life Science Institute, Inc. (Tokyo, Japan) is exclusively responsible for the commercialization and other business operations related to Muse cells.

What's New

Prof. Dezawa's research article 'Muse cell offer new hope for ‘reparative medicine’' was published in Impact.



Muse Cells book has just published by Springer.

This book presents up-to-date knowledge on Muse cells, newly recognized pluripotent stem cells that will be vital for next-generation medical care.


2018.4.5 NAI Fellow Induction Ceremony was held on April 5, 2018 at the Mayflower Hotel, Washington D.C.

Photo Gallery

*Election to NAI Fellow status is the highest professional distinction accorded solely to academic inventors who have demonstrated a prolific spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society.